Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk

Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed...

Full description

Saved in:
Bibliographic Details
Published inCurrent problems in cancer. Case reports Vol. 17; p. 100345
Main Authors Kazi, Bilal, Rumani, Imaan, Kazi, Marzooka Nazim Chishti, Gaikwad, Prashant Manohar
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.03.2025
Elsevier
Subjects
Dyslipidemia
Hematology, Oncology, and Palliative Medicine
Hypertriglyceridemia
Nausea
Olanzapine (Zyprexa)
Nausea
Hypertriglyceridemia
Olanzapine (Zyprexa)
Dyslipidemia
Online AccessGet full text

Cover

More Information
Summary:Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed critically elevated triglycerides (2898 mg/dL) after starting olanzapine for nausea. Her lipid levels significantly improved with medical management, allowing her to proceed for apheresis for the planned CAR-T treatment. This case underscores the need for vigilant metabolic monitoring in patients on Olanzapine (Zyprexa), even those without known risk factors, to prevent serious complications.
ISSN:2666-6219
2666-6219
DOI:10.1016/j.cpccr.2024.100345